These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 20571233)
1. Serum peptide/protein profiling by mass spectrometry provides diagnostic information independently of CA125 in women with an ovarian tumor. Callesen AK; Madsen JS; Iachina M; Vach W; Kruse TA; Jensen ON; Mogensen O Cancer Biomark; 2010; 6(2):73-82. PubMed ID: 20571233 [TBL] [Abstract][Full Text] [Related]
2. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors. Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323 [TBL] [Abstract][Full Text] [Related]
3. [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF]. Zhao Q; Duan W; Wu YM; Qian XH; Deng XH Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):754-8. PubMed ID: 19173805 [TBL] [Abstract][Full Text] [Related]
4. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Petri AL; Simonsen AH; Yip TT; Hogdall E; Fung ET; Lundvall L; Hogdall C Acta Obstet Gynecol Scand; 2009; 88(1):18-26. PubMed ID: 19023702 [TBL] [Abstract][Full Text] [Related]
5. IMMULITE OM-MA assay: a useful diagnostic tool in patients with benign and malignant ovarian tumors. Gebauer G; Rieger M; Jäger W; Lang N Anticancer Res; 1999; 19(4A):2535-6. PubMed ID: 10470190 [TBL] [Abstract][Full Text] [Related]
6. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951 [TBL] [Abstract][Full Text] [Related]
7. Biomarker discovery for ovarian cancer using SELDI-TOF-MS. Zhang H; Kong B; Qu X; Jia L; Deng B; Yang Q Gynecol Oncol; 2006 Jul; 102(1):61-6. PubMed ID: 16403569 [TBL] [Abstract][Full Text] [Related]
8. Characterization of serum biomarkers for detection of early stage ovarian cancer. Kozak KR; Su F; Whitelegge JP; Faull K; Reddy S; Farias-Eisner R Proteomics; 2005 Nov; 5(17):4589-96. PubMed ID: 16237736 [TBL] [Abstract][Full Text] [Related]
9. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Han KQ; Huang G; Gao CF; Wang XL; Ma B; Sun LQ; Wei ZJ Am J Clin Oncol; 2008 Apr; 31(2):133-9. PubMed ID: 18391596 [TBL] [Abstract][Full Text] [Related]
10. [Identification of serum biomarkers for ovarian cancer using protein chips and time of flight mass spectrometry technology]. Wang Q; Li L; Li DR; Zhang W; Wei X; Zhang JQ; Tang Y Zhonghua Fu Chan Ke Za Zhi; 2006 Aug; 41(8):544-8. PubMed ID: 17083841 [TBL] [Abstract][Full Text] [Related]
12. Serum C-reactive protein in the differential diagnosis of ovarian masses. Hefler-Frischmuth K; Hefler LA; Heinze G; Paseka V; Grimm C; Tempfer CB Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):65-8. PubMed ID: 19619929 [TBL] [Abstract][Full Text] [Related]
13. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma. Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D J BUON; 2007; 12(1):99-104. PubMed ID: 17436409 [TBL] [Abstract][Full Text] [Related]
14. Reproducibility of serum protein profiling by systematic assessment using solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry. Callesen AK; Christensen Rd; Madsen JS; Vach W; Zapico E; Cold S; Jørgensen PE; Mogensen O; Kruse TA; Jensen ON Rapid Commun Mass Spectrom; 2008; 22(3):291-300. PubMed ID: 18181248 [TBL] [Abstract][Full Text] [Related]
15. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients]. Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923 [TBL] [Abstract][Full Text] [Related]
16. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer. Kong F; Nicole White C; Xiao X; Feng Y; Xu C; He D; Zhang Z; Yu Y Gynecol Oncol; 2006 Feb; 100(2):247-53. PubMed ID: 16229881 [TBL] [Abstract][Full Text] [Related]
17. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma. Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443 [TBL] [Abstract][Full Text] [Related]
18. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561 [TBL] [Abstract][Full Text] [Related]
19. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma]. Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635 [TBL] [Abstract][Full Text] [Related]
20. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women. Serin IS; Tanriverdi F; Yilmaz MO; Ozcelik B; Unluhizarci K Gynecol Endocrinol; 2008 Mar; 24(3):117-21. PubMed ID: 18335323 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]